welcome
Reuters

Reuters

Health

Health

Biogen proposes to buy remaining stake in Sage in $442 million deal

Reuters
Summary
Nutrition label

80% Informative

Biogen will buy all outstanding shares of Sage Therapeutics that it does not already own for $ 7.22 apiece.

The offer price represents a 30% premium to the stock's close on Friday .

Biogen has been navigating a slow pick-up in sales for its Alzheimer's drug Leqembi in the United States .

VR Score

90

Informative language

94

Neutral language

83

Article tone

formal

Language

English

Language complexity

56

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links